Advertisement

Superior Vena Cava Syndrome in Critically Ill Cancer Patients

  • Victor J. MatosEmail author
Reference work entry

Abstract

Superior vena cava syndrome (SVCS) is the result of any condition that causes obstruction to blood flow. The clinical picture depends on the idiosyncrasies of the patient, location, and time of the obstruction. The diagnosis of SVCS is clinical and is complemented with testing such as computed tomography (CT) and radiography (X-ray) of the thorax. The causes of SVCS range from benign to malignant. However, malignant tumors represent 85–95% of cases with non-small cell lung cancer representing 50% of all malignant causes. SVCS is an oncological emergency; nonetheless, it is an uncommon complication. Each year 15,000 North Americans suffer from this condition, and 10% of patients with left hemithorax malignancies will develop SVCS. In SVCS, a venous obstruction of the superior portion causes increased venous pressure. This leads to a dilation of the superficial collateral veins; facial edema; conjunctival edema, with or without proptosis; and central nervous system (CNS) symptoms. Dyspnea is the most common symptom, followed by chest pain, cough, and stridor, among other signs. Cerebral edema can also be present which produces headache, confusion, and coma. Radiotherapy and chemotherapy continue being first-line treatments with a high success rate. However, the definitive treatment plan depends on the etiology of SVCS. Almost 20 years ago, a recommendation was made to conduct a randomized clinical trial on SVCS comparing particular treatment modalities; such a trial has not yet taken place. Much research is needed, in terms of classification, treatment, and management.

Keywords

Superior vena cava syndrome Oncological obstruction Lung cancer Radiotherapy 

References

  1. 1.
    Zimmerman S, Davis M. Rapid fire: superior vena cava syndrome. Emerg Med Clin N Am. 2018;36:577–84.  https://doi.org/10.1016/j.emc.2018.04.011.CrossRefGoogle Scholar
  2. 2.
    Wilson LD, Detterbeck FC, Yahalom J. Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med. 2007;356:1862–9.  https://doi.org/10.1056/NEJMcp067190.CrossRefPubMedGoogle Scholar
  3. 3.
    Aryana A, Sobota KD, Esterbrooks DJ, Gelbman AI. Superior vena cava syndrome induced by endocardial defibrillator and pacemaker leads. Am J Cardiol. 2007;99:1765–7.  https://doi.org/10.1016/j.amjcard.2007.01.065.CrossRefPubMedGoogle Scholar
  4. 4.
    Zisis C, Skevis K, Kefaloyannis EM, et al. Mediastinal tuberculous lymphadenitis presenting as superior vena cava syndrome. J Thorac Cardiovasc Surg. 2006;131:e11–2.  https://doi.org/10.1016/j.jtcvs.2006.02.003.CrossRefPubMedGoogle Scholar
  5. 5.
    Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: clinical characteristics and evolving etiology. Medicine (Baltimore). 2006;85:37–42.  https://doi.org/10.1097/01.md.0000198474.99876.f0.CrossRefGoogle Scholar
  6. 6.
    Seligson MT, Surowiec SM. Superior Vena Cava Syndrome. [Updated 2019 Feb 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441981/.
  7. 7.
    Gupta V, Ambati SR, Pant P, Bhatia B. Superior vena cava syndrome in children. Indian J Hematol Blood Transfus. 2008;24:28–30.  https://doi.org/10.1007/s12288-008-0020-0.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Yu JB, Wilson LD, Detterbeck FC. Superior vena cava syndrome – a proposed classification system and algorithm for management. J Thorac Oncol. 2008;3:811–4.  https://doi.org/10.1097/JTO.0b013e3181804791.CrossRefPubMedGoogle Scholar
  9. 9.
    Stanford W, Doty DB. The role of venography and surgery in the management of patients with superior vena cava obstruction. Ann Thorac Surg. 1986;41:158–63.CrossRefGoogle Scholar
  10. 10.
    Wudel LJJ, Nesbitt JC. Superior vena cava syndrome. Curr Treat Options Oncol. 2001;2:77–91.CrossRefGoogle Scholar
  11. 11.
    Lepper PM, Ott SR, Hoppe H, et al. Superior vena cava syndrome in thoracic malignancies. Respir Care. 2011;56:653.  https://doi.org/10.4187/respcare.00947.CrossRefPubMedGoogle Scholar
  12. 12.
    Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus. Cochrane Database Syst Rev. 2001;CD001316.  https://doi.org/10.1002/14651858.CD001316.
  13. 13.
    Wilson P, Bezjak A, Asch M, et al. The difficulties of a randomized study in superior vena caval obstruction. J Thorac Oncol. 2007;2:514–9.  https://doi.org/10.1097/JTO.0b013e318060096b.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.National Institute of CancerSanto DomingoDominican Republic

Personalised recommendations